Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175728 | 0.90 | PTGS1 (0.58) | PTGS1PTGS2PDPK1NR3C2CYP2C9 | |
| SCHEMBL5800787 | 0.88 | PTGS2 (0.58) | PTGS1PTGS2PDPK1CYP2C9 | |
| SCHEMBL6451398 | 0.85 | PTGS1 (1.00) | PTGS1PTGS2PDPK1MAPTSMN1; SMN2 | |
| SCHEMBL3281711 | 0.85 | PTGS1 (0.80) | PTGS1PTGS2PDPK1MAPTCYP2C9 | |
| SCHEMBL6268360 | 0.81 | PTGS2 (0.69) | PTGS1PTGS2PDPK1NR3C2CYP2C9 | |
| SCHEMBL3284909 | 0.80 | KDM4E (0.46) | PTGS1PTGS2MAPTTP53THRB | |
| SCHEMBL6094805 | 0.79 | MAPT (0.45) | PTGS1PTGS2MAPTCYP2C9 | |
| Sulfamide SCHEMBL7139961 | 0.78 | PTGS1 (0.83) | PTGS1PTGS2PDPK1CYP2C9 | |
| SCHEMBL6191740 | 0.78 | PTGS2 (0.71) | PTGS1PTGS2CYP2C9 | |
| SCHEMBL2852425 | 0.77 | PTGS1 (0.82) | PTGS1PTGS2PDPK1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1658872-B | Antiallergic agent | INST MED MOLECULAR DESIGN INC | 2010-09-22 | — | — | CN | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| CN-100406006-C | Therapeutic agent for skin pigmentation | INST MED MOLECULAR DESIGN INC (JP) | 2008-07-30 | — | — | CN | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| CN-100379410-C | Therapeutic agent for diabetes | INST MED MOLECULAR DESIGN INC (JP) | 2008-04-09 | — | — | CN | disclosed |
| CN-101103977-A | Therapeutic agent for diabetes | INST MED MOLECULAR DESIGN INC (JP) | 2008-01-16 | — | — | CN | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| CN-1826106-A | Therapeutic agent for skin pigmentation | INST MED MOLECULAR DESIGN INC (JP) | 2006-08-30 | — | — | CN | disclosed |
| CN-1658854-A | Immune related protein kinase inhibitors | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658850-A | Therapeutic agent for diabetes | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658872-A | Antiallergic agent | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658849-A | Inhibitors of AP-1 and NFAT activation | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1495005-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087061-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | PTGS1 89/4885PTGS2 219/4885PDPK1 4171/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | PTGS1 113/4885PTGS2 246/4885PDPK1 4198/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | PTGS1 117/4885PTGS2 271/4885PDPK1 4194/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | PTGS1 1346/4885PTGS2 1676/4885PDPK1 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.